Clinical trials: Acquired Hemophilia A
Acquired Hemophilia A
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
The purpose of this prospective study is to determine the efficacy and safety of Rituximab plus Bortezomib in patients with newly diagnosed acquired hemophilia A.
- Trial name
- NCT03700229
- Testing
- Bortezomib, Rituximab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Peking Union Medical College Hospital
Hemophilia A, Acquired
Emicizumab in Acquired Hemophilia A
This study is an international, multicenter, open-label, single arm, prospective clinical trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with…
- Trial name
- NCT04188639
- Testing
- Emicizumab Injection
- Where
- 16 sites in Austria, Germany
- Volunteers
- 47 people
- Sponsor
- GWT-TUD GmbH
Hemophilia A
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
The purpose of this study is to evaluate the rate of response when administering rituximab to suppress or eliminate the anti-body in a patient's blood that inhibits the effectiveness of their factor replacement product compared…
- Trial name
- NCT00306670
- Testing
- Rituxan, prednisone
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Acquired Haemophilia
Turkish Acquired Haemophilia Registry
Turkish Acquired Haemophilia Registry is a database in which information about clinical features and therapeutic management of acquired haemophilia is collected in Turkey.This is a multicentre, retrospective and prospective…
- Trial name
- EHEM (NCT01403740)
- Testing
- rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
- Where
- Turkey (Türkiye)
- Volunteers
- 250 people
- Sponsor
- Turkish Society of Hematology
HIV Infection, Hemophilia A
Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia
This is an randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of MK-0518 compared to placebo when combined with other antiretroviral drugs, in treatment-experienced HIV-infected…
- Trial name
- NCT00797381
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Public Health Clinical Center
Acquired Hemophilia A
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe and the United States.
- Trial name
- NCT03199794
- Testing
- OBIZUR
- Where
- 26 sites in United States, Austria and 5 more
- Volunteers
- 50 people
- Sponsor
- Baxalta now part of Shire
Acquired Hemophilia A
Study of TAK-672 in Participants With Acquired Hemophilia A
The main aims of the study are to learn if TAK-672 can control bleeds in participants with acquired hemophilia A and if the participants have side effects from TAK-672.
- Trial name
- NCT04580407
- Testing
- TAK-672
- Where
- 9 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Takeda
Acquired Bleeding Disorder, Acquired Haemophilia
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
This trial is conducted in Europe. The aim of this trial is to demonstrate bio-equivalence between the marketed activated recombinant human factor VII (NovoSeven®) (CP-rFVIIa) and a new formulation stable at 25°C (VII25).
- Conditions
- Acquired Bleeding Disorder, Acquired Haemophilia, Congenital Bleeding Disorder, Congenital FVII Deficiency
- Trial name
- NCT01561417
- Testing
- activated recombinant human factor VII
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Novo Nordisk A/S
Acquired Hemophilia A
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world…
- Trial name
- NCT02610127
- Testing
- OBIZUR
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- Baxalta now part of Shire
Acquired Hemophilia A
Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
To provide emergency access to OBI-1 for patients with Acquired Hemophilia and a serious bleeding episode who do not have access to an active clinical study site associated with the OBI-1-301 study.
- Trial name
- NCT01968655
- Testing
- OBI-1
- Where
- 4 sites in United States
- Sponsor
- Baxalta now part of Shire
Acquired Hemophilia A
Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
Purpose: To evaluate the efficacy when administering steroid combined with single dose rituximab to eliminate the antibody in acquired hemophilia A patients compared to treatment using steroid with cyclophosphamide.
- Trial name
- NCT03384277
- Testing
- Steroid, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acquired Hemophilia A
A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
This is a single-center, prospective, single-arm, exploratory study designed to evaluate the efficacy and safety of Bometase Alfa for the on-demand treatment of bleeding episodes in patients with acquired hemophilia A.
- Trial name
- NCT07789587
- Testing
- Bometase Alfa
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acquired Immunodeficiency Syndrome, HIV Infections
Prospective Study of HIV Infection in Hemophiliacs
To examine mechanisms of individual differences in the progression of HIV infection in hemophiliacs.
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections, Blood Disease, Hemophilia A
- Trial name
- NCT00005309
- Sponsor
- Bloodworks
Acquired Hemophilia A
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.
- Trial name
- NCT01178294
- Testing
- OBI-1
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 29 people
- Sponsor
- Baxalta now part of Shire
Liver Decompensation, Hepatocellular Carcinoma
The Second Multicenter Hemophilia Cohort Study
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV).
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT00341705
- Where
- 48 sites in United States, Brazil and 6 more
- Volunteers
- 2,565 people
- Sponsor
- National Cancer Institute (NCI)
Acquired Hemophilia A
A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA).
- Trial name
- NCT06461533
- Testing
- Susoctocog Alfa (Genetical Recombination)
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Takeda
Haemophilia
Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
Occurrence of inhibitors to coagulation factor VIII is diagnosed in ~30% patients with haemophilia A. Presence of inhibitor with a titre >5 BU/ml requires the use of by-passing agents: recombinant activated Factor VIIa…
- Trial name
- Thrombus (NCT01856751)
- Where
- 6 sites in Poland
- Volunteers
- 80 people
- Sponsor
- Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus
HIV Infections
A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
Study A: To determine whether treatment with zidovudine (ZDV) will delay or change the disease process in hemophilic patients who have HIV infection with no symptoms.
- Trial name
- NCT00001104
- Testing
- Zidovudine
- Where
- 23 sites in United States
- Volunteers
- 538 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Hemophilia A
Emicizumab in Patients With Acquired Hemophilia A
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
- Trial name
- AHAEmi (NCT05345197)
- Testing
- emicizumab
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Washington
Hemophilia A
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused…
- Trial name
- IMMUNHEMAC (NCT04805021)
- Testing
- no intervention
- Where
- 2 sites in France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital